Rezultati pretraživanja
  1. 21. stu 2019.

    Amy Abernethy of the FDA: 800 active INDs for cell and gene therapy. That's just crazy huge. Wonder what the breakdown is for gene replacement for rare genetic diseases vs engineered immune cells in cancer.

  2. This morning, I had the chance to kick off the inaugural Summit. What a great line up of biopharma researchers, policymakers and patient advocates to discuss advances in science and emerging challenges that we need to address to continue to push forward.

  3. Active debate about drug prices among biotech execs here at . “Unfortunately, I think the industry has earned” its bad reputation, says Bluebird Bio’s Nick Leschly.

  4. SPICY! --> top scientist nearly dares FDA not to approve Alzheimer’s drug

  5. 20. stu 2019.

    Speechless to see in person the future of bionic limbs at - absolutely unbelievable that this kind of technology is a reality. Jim’s story- a future STAT documentary- is a must watch.

  6. 21. stu 2019.

    . with an eye opening (as always) argument on whether our drug pricing system is prioritizing the right things. “I'm thrilled that we now have a treatment for ROS1, but I'm really worried that people are dying of suicides and opioid overdoses.”

  7. Talking with Erich Wohlhieter of about the future of AI and health care. He spoke about Crystal Bone project that analyzed a huge amount of patient data and can now predict a bone break due to osteoporosis with patients, so can predict and prevent.

  8. Had a great convo with at about the great work we are doing , including actions we’re taking to advance the technology we use to fulfill our public health mission as part of our Technology Modernization Action Plan.

    Prikaži ovu nit
  9. says scientific studies should be freely available to families searching for disease treatments.

  10. 21. stu 2019.

    Julie Grant, partner at VC firm Canaan: “we really have to listen to orgs like Walgreens and CVS when they say that people with cancer dont buy the drug, if they pay more than $300.“ Says industry needs to be focusing on that target out of pocket cost.

  11. Anthony Yanni, SVP & Global Head, Patient Centricity, spoke at today’s about what it means to be patient centric. “Integration of the patient perspective must start much earlier in, and be incorporated throughout, the drug discovery, development & delivery process.”

  12. great to chat with Dr. Charles Sawyers, who helped lead the development of the cancer drugs Gleevec and Xtandi

  13. Prikaži ovu nit
  14. 21. stu 2019.

    Looking forward to speaking at , will cover innovation incentives and that they work, maybe too well. The gains are not distributed across society even though the costs are.

  15. 21. stu 2019.

    “Artificial intelligence can help disrupt the conversation of cells in a precise, targeted way while the important conversations continue to flow.” – , Principle Senior Scientist, on in biomedicine at today’s .

  16. Provocative conversation today led by with biotech CEOs. They stated that they believed that the negative reputation of some biopharma companies was earned — particularly because of some drug pricing decisions.

  17. 21. stu 2019.

    If FDA approves aducanumab, running a placebo-controlled study will be difficult, says 's Al Sandrock in response to question from if Biogen should do second trial.

  18. Jim Wilson says it's "kind of embarrassing" that the gene therapy technique he discovered in 2003 is still the best thing we've got

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.